$AXDX
Accelerate Diagnostics, Inc Stock $axdx

$axdx Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000162828016012510 Filed on March 09, 2016

Income Statement

Concept	2015	2014 Q4	2014 Q3
Revenue	$147.0K	$79.00K	$16.00K
YoY Change	20.49%	690.0%	60.0%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$147.0K
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$17.88M	$2.580M	$2.630M
YoY Change	67.1%	84.29%	150.48%
% of Gross Profit	12163.27%
Research & Development	$27.14M	$5.450M	$5.950M
YoY Change	39.0%	48.1%	124.53%
% of Gross Profit	18463.95%
Depreciation & Amortization	$1.800M	$290.0K	$270.0K
YoY Change	120.32%	141.67%	170.0%
% of Gross Profit	1224.49%
Operating Expenses	$27.14M	$8.330M	$8.840M
YoY Change	39.0%	60.5%	132.02%
Operating Profit	-$45.55M
YoY Change	46.98%
Interest Expense	$50.00K	$10.00K	$10.00K
YoY Change	-16.67%	-66.67%
% of Operating Profit
Other Income/Expense, Net	$0.00
YoY Change	-100.0%
Pretax Income	-$45.50M	-$8.240M	-$8.810M
YoY Change	47.09%	59.69%	131.84%
Income Tax	$0.00	$530.0K	$0.00
% Of Pretax Income
Net Earnings	-$45.50M	-$8.765M	-$8.814M
YoY Change	47.09%	69.86%	131.95%
Net Earnings / Revenue	-30951.02%	-11094.94%	-55087.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.011M	-$196.5K	-$197.6K
COMMON SHARES
Basic Shares Outstanding	45.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.4M	$66.70M	$71.90M
YoY Change	98.5%	58.81%	61.94%
Cash & Equivalents	$120.6M	$53.56M	$57.90M
Short-Term Investments	$11.80M	$13.10M	$14.10M
Other Short-Term Assets	$1.600M	$0.00	$700.0K
YoY Change	433.33%	-100.0%	600.0%
Inventory
Prepaid Expenses
Receivables	$100.0K	$100.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$134.2M	$67.10M	$72.70M
YoY Change	100.0%	59.38%	63.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.000M	$2.536M	$2.300M
YoY Change	100.0%	153.6%	130.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.100M	$2.703M	$2.500M
YoY Change	88.89%	107.92%	92.31%
TOTAL ASSETS
Total Short-Term Assets	$134.2M	$67.10M	$72.70M
Total Long-Term Assets	$5.100M	$2.703M	$2.500M
Total Assets	$139.3M	$69.80M	$75.20M
YoY Change	99.57%	60.83%	63.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.600M	$2.129M	$1.100M
YoY Change	23.81%	325.8%
Accrued Expenses	$2.500M	$500.0K	$700.0K
YoY Change	400.0%	0.0%	133.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$100.0K	$100.0K
YoY Change	-100.0%
Total Short-Term Liabilities	$5.300M	$2.783M	$2.100M
YoY Change	89.29%	153.0%	425.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$100.0K
YoY Change
Other Long-Term Liabilities	$1.000M	$1.000M	$800.0K
YoY Change	0.0%	25.0%	60.0%
Total Long-Term Liabilities	$1.000M	$1.000M	$900.0K
YoY Change	0.0%	25.0%	80.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.300M	$2.783M	$2.100M
Total Long-Term Liabilities	$1.000M	$1.000M	$900.0K
Total Liabilities	$6.300M	$3.810M	$2.900M
YoY Change	65.79%	100.53%	222.22%
SHAREHOLDERS EQUITY
Retained Earnings		-$65.42M
YoY Change
Common Stock		$131.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$133.0M	$65.99M	$72.30M
YoY Change
Total Liabilities & Shareholders Equity	$139.3M	$69.80M	$75.20M
YoY Change	99.57%	60.83%	63.83%

Cashflow Statement

Concept	2015	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$45.50M	-$8.765M	-$8.814M
YoY Change	47.09%	69.86%	131.95%
Depreciation, Depletion And Amortization	$1.800M	$290.0K	$270.0K
YoY Change	120.32%	141.67%	170.0%
Cash From Operating Activities	-$35.13M	-$4.800M	-$6.180M
YoY Change	86.99%	74.55%	119.15%
INVESTING ACTIVITIES
Capital Expenditures	-$3.660M	-$570.0K	-$630.0K
YoY Change	89.64%	714.29%	231.58%
Acquisitions
YoY Change
Other Investing Activities	$980.0K	$920.0K	-$400.0K
YoY Change	-168.06%	-186.79%	-96.35%
Cash From Investing Activities	-$2.675M	$350.0K	-$1.030M
YoY Change	-20.67%	-130.97%	-90.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$104.8M	160.0K	-150.0K
YoY Change	129.42%	-64.44%	-100.74%
NET CHANGE
Cash From Operating Activities	-$35.13M	-4.800M	-6.180M
Cash From Investing Activities	-$2.675M	350.0K	-1.030M
Cash From Financing Activities	$104.8M	160.0K	-150.0K
Net Change In Cash	$67.02M	-4.290M	-7.360M
YoY Change	184.79%	25.07%	-217.01%
FREE CASH FLOW
Cash From Operating Activities	-$35.13M	-$4.800M	-$6.180M
Capital Expenditures	-$3.660M	-$570.0K	-$630.0K
Free Cash Flow	-$31.47M	-$4.230M	-$5.550M
YoY Change	86.69%	57.84%	111.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	axdx	Additional Exercised Class Of Warrant Or Right Exercise Price Of Warrants Or Rights AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.00
CY2012Q2	axdx	Additional Exercised Class Of Warrant Or Right Exercise Price Of Warrants Or Rights2 AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2	2.00
CY2013Q1	axdx	Additional Exercisedl Option Indexed To Issuers Equity Indexed Shares AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares	6400000	shares
CY2012Q2	axdx	Additional Option Indexed To Issuers Equity Indexed Shares AdditionalOptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2013Q1	axdx	Additional Option Indexed To Issuers Equity Indexed Shares AdditionalOptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2012Q2	axdx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights3 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3	1.03
CY2013Q1	axdx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights3 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3	1.03
CY2015	axdx	Clinical Trial Agreement Expense ClinicalTrialAgreementExpense	1600000	USD
CY2015Q4	axdx	Clinical Trial Agreement Liability ClinicalTrialAgreementLiability	512000	USD
CY2012Q2	axdx	Common Stock And Warrants Issued Value CommonStockAndWarrantsIssuedValue	14400000	USD
CY2014Q4	axdx	Deferred Revenue Research Use Only DeferredRevenueResearchUseOnly	0	USD
CY2015Q4	axdx	Deferred Revenue Research Use Only DeferredRevenueResearchUseOnly	114000	USD
CY2014Q4	axdx	Deferred Tax Assets Finite Lived Intangible Assets DeferredTaxAssetsFiniteLivedIntangibleAssets	421000	USD
CY2015Q4	axdx	Deferred Tax Assets Finite Lived Intangible Assets DeferredTaxAssetsFiniteLivedIntangibleAssets	333000	USD
CY2013	axdx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	0.0000
CY2014	axdx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	0.0000
CY2015	axdx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	0.0011
CY2015	axdx	Employee Service Sharebased Compensation Numberof Plans EmployeeServiceSharebasedCompensationNumberofPlans	4	plan
CY2015Q4	axdx	Exercised Warrant Amount Unexercised ExercisedWarrantAmountUnexercised	571160	shares
CY2013Q1	axdx	Exercised Warrant Percent Exercised ExercisedWarrantPercentExercised	0.92
CY2013Q1	axdx	Exercisedl Option Indexed To Issuers Equity Indexed Shares ExercisedlOptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2015Q4	axdx	Proceeds From Saleof Common Stock Gross ProceedsFromSaleofCommonStockGross	109300000	USD
CY2013Q3	axdx	Proceedsfrom Issuanceof Warrants Gross ProceedsfromIssuanceofWarrantsGross	20000000	USD
CY2014Q2	axdx	Proceedsfrom Issuanceof Warrants Gross ProceedsfromIssuanceofWarrantsGross	45000000	USD
CY2012Q3	axdx	Revenue Recognition Milestone Method Annual Wages Minimum RevenueRecognitionMilestoneMethodAnnualWagesMinimum	63000	USD
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Four RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour	65	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone One RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne	15	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Three RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree	40	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Two RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo	30	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Minimum Capital Investment RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment	4500000	USD
CY2012Q3	axdx	Revenue Recognition Milestone Method Number Of Milestones RevenueRecognitionMilestoneMethodNumberOfMilestones	4	milestone
CY2012Q3	axdx	Revenue Recognition Milestone Method Percentof Company Paid Premiums RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums	0.65
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant2 ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2	0	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant3 ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3	0	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant4 ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4	2945459	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant5 ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5	0	shares
CY2013	axdx	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Forfeitures1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1	0.140
CY2014	axdx	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Forfeitures1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1	0.004
CY2015	axdx	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Forfeitures1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1	0.056
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisaed Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber	527500	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Number1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1	270000	shares
CY2014	axdx	Sharebased Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term2 SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2	6.25	Y
CY2015	axdx	Sharebased Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term2 SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2	6.26	Y
CY2015Q4	axdx	Underwriting Discountand Commission Fees Per Share UnderwritingDiscountandCommissionFeesPerShare	1.19
CY2013	axdx	Unrecognized Tax Benefits Other Decrease UnrecognizedTaxBenefitsOtherDecrease	0	USD
CY2014	axdx	Unrecognized Tax Benefits Other Decrease UnrecognizedTaxBenefitsOtherDecrease	0	USD
CY2015	axdx	Unrecognized Tax Benefits Other Decrease UnrecognizedTaxBenefitsOtherDecrease	0	USD
CY2013	axdx	Unrecognized Tax Benefits Other Increase UnrecognizedTaxBenefitsOtherIncrease	0	USD
CY2014	axdx	Unrecognized Tax Benefits Other Increase UnrecognizedTaxBenefitsOtherIncrease	0	USD
CY2015	axdx	Unrecognized Tax Benefits Other Increase UnrecognizedTaxBenefitsOtherIncrease	0	USD
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Number2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2	403474	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Number3 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3	71147	shares
CY2014Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1	0	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1	40250	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1	10000	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2	3536526	shares
CY2015Q4	axdx	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number3 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3	2660894	shares
CY2015	axdx	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price1 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1	0.00
CY2015	axdx	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price1 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1	20.91
CY2013	axdx	Sharebased Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term2 SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2	6.28	Y
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0000727207
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51199017	shares
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	483400000	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	Accelerate Diagnostics, Inc.
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	494000	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2543000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2129000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2623000	USD
CY2014Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	13000	USD
CY2015Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	127000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1311000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2622000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities	-7000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities	12000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	131356000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	243894000	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	77000	USD
CY2015	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss	-20000	USD
CY2014Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	147000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	71000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5731246	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6174886	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6778580	shares
CY2013	us-gaap	Asset Impairment Charges AssetImpairmentCharges	11000	USD
CY2014	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3000	USD
CY2015	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2014Q4	us-gaap	Assets Assets	69801000	USD
CY2015Q4	us-gaap	Assets Assets	139324000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	67098000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	134151000	USD
CY2014Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	26242000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	17060000	USD
CY2013	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss	22000	USD
CY2014	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss	-15000	USD
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	13000	USD
CY2014Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	266000	USD
CY2015Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	266000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	13000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	13000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	0	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	0	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	13000	USD
CY2014Q4	us-gaap	Capital Leases Net Investment In Direct Financing Leases Accumulated Amortization CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization	-133000	USD
CY2015Q4	us-gaap	Capital Leases Net Investment In Direct Financing Leases Accumulated Amortization CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization	-266000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12069000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30029000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53563000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120585000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	17960000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23534000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	67022000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	14000000	shares
CY2014Q4	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	45000	USD
CY2015Q4	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	51000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44639829	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51199017	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44639829	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51199017	shares
CY2012Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	8500000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15260000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30948000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45517000	USD
CY2015Q4	us-gaap	Contractual Obligation ContractualObligation	1129000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	15359000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	31112000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	45696000	USD
CY2012Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.03
CY2013Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.04
CY2014Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	16.80
CY2012Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	650000	USD
CY2013Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	700000	USD
CY2014Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2014Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2015Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2015Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2012Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	13000	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	127000	USD
CY2014Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1014000	USD
CY2015Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1000000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2015Q4	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	114000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	13000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	18000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	380000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	372000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	620000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	864000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15492000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28584000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	187000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	77000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	339000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	885000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	1915000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3644000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5208000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21500000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21532000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37800000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37820000	USD
CY2013	us-gaap	Depreciation Depreciation	286000	USD
CY2014	us-gaap	Depreciation Depreciation	817000	USD
CY2015	us-gaap	Depreciation Depreciation	1782000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	286000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	817000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1782000	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3880
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3380
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3581
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0320
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0080
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0267
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0042
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0100
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0050
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0120
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0370
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0286
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0380
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0320
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0293
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.0000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.0040
CY2013	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3828000	USD
CY2014	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	9624000	USD
CY2015	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	8388000	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11400000	USD
CY2013	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	6.05
CY2014	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	12.63
CY2015	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	16.69
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	167000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157000	USD
CY2014Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	1625000	USD
CY2015Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	1806000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1083000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15282000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-30933000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45498000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.12
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.19
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.20
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	842000	USD
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1772000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4312000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10695000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17882000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15282000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-30933000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-44415000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2014Q4	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.20
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.20
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.27
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.25
CY2015Q4	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.29
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	205000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1336000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	329000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-739000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	54000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-356000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	80000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	827000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	781000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	168000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	100000	USD
CY2013	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2014	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	12000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	114000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	166000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1241000	USD
CY2013Q3	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	88000	USD
CY2014Q2	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	125000	USD
CY2013	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	0	USD
CY2014	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	7000	USD
CY2015	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	4000	USD
CY2013	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	-76000	USD
CY2014	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	-269000	USD
CY2015	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	-188000	USD
CY2013	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	29000	USD
CY2014	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	64000	USD
CY2015	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	74000	USD
CY2014Q4	us-gaap	Investments Investments	13115000	USD
CY2015Q4	us-gaap	Investments Investments	11839000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	19912000	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	44875000	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	104165000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	168000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	293000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	685000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	3810000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	6306000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	69801000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	139324000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2783000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5306000	USD
CY2014Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1014000	USD
CY2015Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1000000	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	48000	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	122000	USD
CY2015	us-gaap	Licenses Revenue LicensesRevenue	71000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	13000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	0	USD
CY2014Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1020000	USD
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1877000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40881000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45691000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	104823000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13172000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3372000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2675000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9749000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18785000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35126000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-15282000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-5202000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-8152000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-8814000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-8765000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-30933000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-8897000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-12252000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-11186000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-13163000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-45498000	USD
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-15311000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-30990000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-45549000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	954000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	171000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2012Q2	us-gaap	Option Indexed To Issuers Equity Indexed Shares OptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	0	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000	USD
CY2013	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2014	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	7000	USD
CY2015	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	23000	USD
CY2013	us-gaap	Other Expenses OtherExpenses	11000	USD
CY2014	us-gaap	Other Expenses OtherExpenses	3000	USD
CY2015	us-gaap	Other Expenses OtherExpenses	0	USD
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	29000	USD
CY2014	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	57000	USD
CY2015	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	51000	USD
CY2013	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2014	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2015	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2015Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5900000	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12014000	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7657000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12418000	USD
CY2013	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1158000	USD
CY2014	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1933000	USD
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3656000	USD
CY2013	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	96000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	342000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1638000	USD
CY2015	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2015Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103400000	USD
CY2015	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	805000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	861000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	141000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5357000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13258000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20969000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	923000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	805000	USD
CY2013Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20100000	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-15282000	USD
CY2014	us-gaap	Profit Loss ProfitLoss	-30933000	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-45498000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3980000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7904000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2536000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5016000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	227000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	2183000	USD
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	78000	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	77000	USD
CY2013	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	0	USD
CY2014	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	107000	USD
CY2015	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	147000	USD
CY2015Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	5000000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	689000	USD
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
CY2014	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
CY2015	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	483000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10673000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19526000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26022000	USD
CY2013	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2014	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	527000	USD
CY2015	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	647000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65417000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110915000	USD
CY2013	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	0	USD
CY2014	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	0	USD
CY2015	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	76000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	48000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	14000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	13000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	16000	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	79000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	122000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	14000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	19000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	92000	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	22000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	147000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	3828000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	9624000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	8388000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	40250	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.00
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	20.91
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.00
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.97
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.96
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.91
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2500000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2700000	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4000000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5500000	shares
CY2004Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	500000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1677500	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5677500	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1536520	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.11
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	13678	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	54505	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	769055	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	717833	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5185086	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5628726	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6167170	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.45
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.20
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.91
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	0	shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.96
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.44
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.06
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.71
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.22
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.59
CY2015Q4	us-gaap	Share Price SharePrice	21.49
CY2014Q2	us-gaap	Share Price SharePrice	17.54
CY2014Q2	us-gaap	Share Price SharePrice	17.64
CY2015Q4	us-gaap	Share Price SharePrice	17.00
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5900000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	600000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3800000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7300000	USD
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	311737	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	124884	shares
CY2013	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	20969000	USD
CY2014	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	923000	USD
CY2015	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	805000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19912000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	44875000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	103351000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2600000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3800000	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	12068000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	41517000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	65991000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	133018000	USD
CY2013Q3	us-gaap	Temporary Equity Share Subscriptions TemporaryEquityShareSubscriptions	0.064038	shares
CY2014Q1	us-gaap	Temporary Equity Share Subscriptions TemporaryEquityShareSubscriptions	0.063921	shares
CY2013	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	22000	USD
CY2014	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-15000	USD
CY2015	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-20000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	161000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	343000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	83000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	182000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	78000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2014Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	45000000	USD
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37599000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43626000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44998000	shares
CY2015	axdx	License Agreement LicenseAgreement	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. LICENSE AGREEMENTS AND GRANTS</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Defense Medical Research and Development Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (“DMRDP”) recommended </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;"> of funding for a proposed 35-month project. The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections. The project will apply the Accelerate ID/AST system to wound infections and other serious infections secondary to trauma. The Company has invoiced a cumulative total of </font><font style="font-family:Arial;font-size:10pt;">$558,000</font><font style="font-family:Arial;font-size:10pt;"> under this grant which is recorded as an offset to research and development expenses. The amount invoiced for the years ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$179,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$221,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$143,000</font><font style="font-family:Arial;font-size:10pt;">, respectively. The period of performance for the grant ended September 2015.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">National Institute of Health Grant</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2015, the National Institute of Health awarded Denver Health and the Company a five year, </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;"> grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood. In June 2015, the Company executed a subaward agreement with Denver Health for the services we will provide as part of this grant which covers the period of February 15, 2015 through January 31, 2016 and totals </font><font style="font-family:Arial;font-size:10pt;">$689,000</font><font style="font-family:Arial;font-size:10pt;">. The amounts invoiced for the years ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$483,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona Commerce Authority</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least </font><font style="font-family:Arial;font-size:10pt;">$4.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least </font><font style="font-family:Arial;font-size:10pt;">$63,000</font><font style="font-family:Arial;font-size:10pt;"> and offers health insurance benefits and pays at least </font><font style="font-family:Arial;font-size:10pt;">65%</font><font style="font-family:Arial;font-size:10pt;"> of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company has collected all of the </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestones. The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are “claw-back” provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the “claw-back” provisions expire in January 2018, we will recognize the grant as an offset to expense. Further details are included in </font><font style="font-family:Arial;font-size:10pt;">Note 7, Deferred Revenue and Income</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has applied for and met the program requirements to receive a “Certificate of Qualification” from the Arizona Commerce Authority (“Authority”) which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&D Refundable Tax Credit Program"). The amounts collected under this program are recorded as an offset to research and development expenses, and for the years ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$647,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$527,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively. If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div></div>
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company’s main financial institution for banking operations held </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">83%</font><font style="font-family:Arial;font-size:10pt;"> of the Company’s cash and cash equivalents as of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2014</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. At </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">66%</font><font style="font-family:Arial;font-size:10pt;"> of the outstanding receivable balance was with Denver Health. See </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;"> for more information.</font></div></div>
CY2015	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. DEFERRED REVENUE AND INCOME</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income. A summary of the balances as of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Revenue and Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research Use Only Accelerate ID/AST systems</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current deferred revenue and income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arizona Commerce Authority grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term deferred income</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through December 31, 2014, we received </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;">, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the “claw-back” provisions under the Grant Agreement expire in January 2018.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred income includes </font><font style="font-family:Arial;font-size:10pt;">$114,000</font><font style="font-family:Arial;font-size:10pt;"> of payments received in December 2015, for Research Use Only Accelerate ID/AST systems.</font></div></div>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-012510-index-headers.html	Edgar Link	pending
0001628280-16-012510-index.html	Edgar Link	pending
0001628280-16-012510.txt	Edgar Link	pending
0001628280-16-012510-xbrl.zip	Edgar Link	pending
accelerate-12312015xexh21.htm	Edgar Link	pending
accelerate-12312015xexh231.htm	Edgar Link	pending
accelerate-12312015xexh311.htm	Edgar Link	pending
accelerate-12312015xexh312.htm	Edgar Link	pending
accelerate-12312015xexh32.htm	Edgar Link	pending
axdx-123115x10k.htm	Edgar Link	pending
axdx-123115_chartx42354a.jpg	Edgar Link	pending
axdx-20151231.xml	Edgar Link	completed
axdx-20151231.xsd	Edgar Link	pending
axdx-20151231_cal.xml	Edgar Link	unprocessable
axdx-20151231_def.xml	Edgar Link	unprocessable
axdx-20151231_lab.xml	Edgar Link	unprocessable
axdx-20151231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AXDX
Accelerate Diagnostics, Inc Stock $axdx

2015 Form 10-K Financial Statement

#000162828016012510 Filed on March 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXDX Accelerate Diagnostics, Inc Stock $axdx

2015 Form 10-K Financial Statement

#000162828016012510 Filed on March 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXDX
Accelerate Diagnostics, Inc Stock $axdx